News coverage about Aeglea BioTherapeutics (NASDAQ:AGLE) has been trending somewhat positive on Sunday, Accern Sentiment Analysis reports. The research group scores the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Aeglea BioTherapeutics earned a media sentiment score of 0.13 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 46.3419850610449 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Several brokerages recently weighed in on AGLE. TheStreet cut Aeglea BioTherapeutics from a “c-” rating to a “d+” rating in a research note on Friday, May 26th. ValuEngine cut Aeglea BioTherapeutics from a “sell” rating to a “strong sell” rating in a research note on Thursday, July 6th. Finally, Zacks Investment Research raised Aeglea BioTherapeutics from a “hold” rating to a “buy” rating and set a $3.75 price target on the stock in a research note on Thursday, August 3rd.

Aeglea BioTherapeutics (NASDAQ AGLE) traded up 2.06% during midday trading on Friday, hitting $2.97. The stock had a trading volume of 29,444 shares. The stock’s market cap is $48.86 million. Aeglea BioTherapeutics has a 52-week low of $2.81 and a 52-week high of $10.34. The company’s 50 day moving average price is $3.39 and its 200-day moving average price is $5.16.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by Daily Political and is owned by of Daily Political. If you are viewing this piece on another website, it was stolen and republished in violation of United States and international trademark and copyright law. The legal version of this piece can be accessed at

About Aeglea BioTherapeutics

Aeglea BioTherapeutics, Inc is a biotechnology company, which is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. The Company’s product pipeline includes AEB1102, AEB3103, AEB2109 and AEB4104. Its lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is being developed to treat over two extremes of arginine metabolism, including arginine excess in patients with Arginase I deficiency, an IEM, as well as some cancers, which have shown to have a metabolic dependence on arginine.

Receive News & Ratings for Aeglea BioTherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea BioTherapeutics Inc. and related companies with's FREE daily email newsletter.